TRCT
CL icon

Tower Research Capital (TRC)’s Colgate-Palmolive CL Stock Holding History

Tower Research Capital (TRC)’s Portfolio CL Stock Details CL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Sell
14,901
-7,213
-33% -$643K 0.03% 465
2025
Q4 		$1.75M Sell
22,114
-6,531
-23% -$512K 0.04% 371
2025
Q3 		$2.29M Buy
28,645
+11,232
+65% +$958K 0.06% 264
2025
Q2 		$1.58M Sell
17,413
-49,327
-74% -$4.5M 0.04% 369
2025
Q1 		$6.25M Buy
66,740
+3,056
+5% +$274K 0.19% 81
2024
Q4 		$5.79M Buy
63,684
+32,582
+105% +$3.11M 0.11% 139
2024
Q3 		$3.23M Sell
31,102
-13,414
-30% -$1.37M 0.09% 167
2024
Q2 		$4.32M Buy
44,516
+14,601
+49% +$1.35M 0.07% 230
2024
Q1 		$2.69M Sell
29,915
-72,747
-71% -$6.16M 0.06% 216
2023
Q4 		$8.18M Buy
102,662
+62,654
+157% +$4.71M 0.1% 160
2023
Q3 		$2.84M Sell
40,008
-17,496
-30% -$1.31M 0.09% 211
2023
Q2 		$4.43M Sell
57,504
-17,594
-23% -$1.36M 0.15% 96
2023
Q1 		$5.64M Buy
75,098
+42,430
+130% +$3.16M 0.18% 66
2022
Q4 		$2.57M Sell
32,668
-38,165
-54% -$2.86M 0.11% 136
2022
Q3 		$4.98M Sell
70,833
-4,425
-6% -$347K 0.08% 194
2022
Q2 		$6.03M Sell
75,258
-48,216
-39% -$3.77M 0.14% 119
2022
Q1 		$9.36M Buy
123,474
+53,679
+77% +$4.25M 0.09% 196
2021
Q4 		$5.96M Buy
69,795
+40,452
+138% +$3.16M 0.1% 166
2021
Q3 		$2.22M Buy
29,343
+3,443
+13% +$273K 0.06% 241
2021
Q2 		$2.11M Sell
25,900
-57,945
-69% -$4.74M 0.05% 287
2021
Q1 		$6.61M Buy
83,845
+48,149
+135% +$3.77M 0.11% 160
2020
Q4 		$3.05M Buy
35,696
+13,455
+60% +$1.11M 0.09% 141
2020
Q3 		$1.72M Buy
22,241
+12,743
+134% +$972K 0.02% 505
2020
Q2 		$695K Buy
9,498
+9,288
+4,423% +$660K 0.03% 763
2020
Q1 		$14K Buy
+210
New +$14.8K ﹤0.01% 1867
2019
Q4 		– Sell
-13,488
Closed -$992K – 3623
2019
Q3 		$992K Buy
13,488
+12,438
+1,185% +$902K 0.07% 289
2019
Q2 		$75K Sell
1,050
-13,322
-93% -$946K 0.01% 1333
2019
Q1 		$985K Sell
14,372
-28,147
-66% -$1.82M 0.06% 289
2018
Q4 		$2.53M Buy
42,519
+38,842
+1,056% +$2.43M 0.18% 120
2018
Q3 		$246K Sell
3,677
-7,400
-67% -$493K 0.02% 857
2018
Q2 		$718K Buy
11,077
+9,877
+823% +$646K 0.04% 474
2018
Q1 		$86K Sell
1,200
-7,966
-87% -$573K 0.01% 1363
2017
Q4 		$691K Buy
9,166
+6,671
+267% +$487K 0.09% 227
2017
Q3 		$182K Buy
2,495
+1,816
+267% +$131K 0.02% 836
2017
Q2 		$50K Buy
679
+441
+185% +$32.7K 0.01% 746
2017
Q1 		$17K Sell
238
-20,929
-99% -$1.47M ﹤0.01% 1385
2016
Q4 		$1.39M Buy
21,167
+20,944
+9,392% +$1.44M 0.15% 152
2016
Q3 		$16K Sell
223
-6,169
-97% -$456K ﹤0.01% 1740
2016
Q2 		$468K Buy
+6,392
New +$455K 0.04% 292
2016
Q1 		– Sell
-202
Closed -$13K – 4193
2015
Q4 		$13K Sell
202
-565
-74% -$37.6K ﹤0.01% 1774
2015
Q3 		$49K Sell
767
-1,402
-65% -$91.6K ﹤0.01% 1031
2015
Q2 		$142K Buy
2,169
+2,069
+2,069% +$140K 0.01% 572
2015
Q1 		$7K Buy
100
+15
+18% +$1.04K ﹤0.01% 3027
2014
Q4 		$6K Sell
85
-3,022
-97% -$204K ﹤0.01% 2565
2014
Q3 		$202K Buy
3,107
+1,590
+105% +$105K 0.02% 520
2014
Q2 		$103K Sell
1,517
-2,869
-65% -$192K 0.01% 884
2014
Q1 		$285K Buy
4,386
+3,122
+247% +$197K 0.04% 312
2013
Q4 		$82K Sell
1,264
-28,110
-96% -$1.8M 0.01% 975
2013
Q3 		$1.74M Buy
+29,374
New +$1.74M 0.19% 103

Other funds holding CL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Tower Research Capital (TRC)'s CL Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Colgate-Palmolive (CL) stake by 33% in Q1 2026, selling an estimated $643K and leaving 14,901 shares worth $1.27M. The position accounts for 0.03% of the portfolio, ranked #465.

Tower Research Capital (TRC) first reported a position in CL in Q3 2013 and has held it in 49 quarters since. The position peaked at $9.36M in Q1 2022. 1,946 funds tracked by Wall St. Rank hold CL as of Q1 2026.

  • Tower Research Capital (TRC) held 14,901 shares of Colgate-Palmolive worth $1.27M as of Q1 2026.
  • Tower Research Capital (TRC) sold 7,213 Colgate-Palmolive shares in Q1 2026, an estimated $643K.
  • Colgate-Palmolive made up 0.03% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #465 holding.
  • Tower Research Capital (TRC) first reported a position in Colgate-Palmolive in Q3 2013 and has held it in 49 quarters since.
  • Tower Research Capital (TRC)'s Colgate-Palmolive position peaked at $9.36M in Q1 2022.
  • 1,946 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.